At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Radezolid +2 moredrug
Likely dose
Radezolid 450mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection
In Brief
A Phase 2 clinical trial evaluating Radezolid and Linezolid for Infectious Skin Diseases and 4 related conditions. Completed, enrolled 150 participants across 19 sites.
Detailed Summary
The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedMar 2008
Primary CompletionApr 2008
TodayJul 2026
First PostedMar 31, 2008
Enrollment StartDec 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.3 years ago
Interventions
Radezoliddrug
450mg PO QD
Radezoliddrug
450mg PO BID
Linezoliddrug
600mg PO BID